T细胞幼淋巴细胞白血病中对BCL2和MCL1的双重依赖。
Dual dependence on BCL2 and MCL1 in T-cell prolymphocytic leukemia.
作者信息
Smith Victoria M, Lomas Oliver, Constantine Donna, Palmer Lianne, Schuh Anna H, Bruce David, Gonchar Oksana, Macip Salvador, Jayne Sandrine, Dyer Martin J S, Eyre Toby A
机构信息
Mechanisms of Cancer and Ageing Laboratory, Department of Molecular and Cell Biology, and.
The Ernest and Helen Scott Haematological Research Institute, University of Leicester, Leicester, United Kingdom.
出版信息
Blood Adv. 2020 Feb 11;4(3):525-529. doi: 10.1182/bloodadvances.2019000917.
Abstract
Treatment of relapsed refractory T-PLL with venetoclax monotherapy results in only transient and minor clinical responses. In vitro analyses pre- and postvenetoclax indicate dual dependence on BCL2 and MCL1; combined BCL2 and MCL1 inhibition are synergistic.
摘要
用维奈克拉单药治疗复发难治性T细胞幼淋巴细胞白血病仅产生短暂和轻微的临床反应。维奈克拉治疗前后的体外分析表明对BCL2和MCL1存在双重依赖性；联合抑制BCL2和MCL1具有协同作用。
相似文献
1
Dual dependence on BCL2 and MCL1 in T-cell prolymphocytic leukemia.T细胞幼淋巴细胞白血病中对BCL2和MCL1的双重依赖。
Blood Adv. 2020 Feb 11;4(3):525-529. doi: 10.1182/bloodadvances.2019000917.
2
Enhanced stability of Mcl1, a prosurvival Bcl2 relative, blunts stress-induced apoptosis, causes male sterility, and promotes tumorigenesis.Mcl1 是一种抗凋亡 Bcl2 相关蛋白，稳定性增强会削弱应激诱导的细胞凋亡，导致雄性不育，并促进肿瘤发生。
Proc Natl Acad Sci U S A. 2014 Jan 7;111(1):261-6. doi: 10.1073/pnas.1321259110. Epub 2013 Dec 20.
3
Expression Ratios of the Antiapoptotic BCL2 Family Members Dictate the Selective Addiction of Kaposi's Sarcoma-Associated Herpesvirus-Transformed Primary Effusion Lymphoma Cell Lines to MCL1.抗凋亡 BCL2 家族成员的表达比率决定了卡波氏肉瘤相关疱疹病毒转化的原发性渗出性淋巴瘤细胞系对 MCL1 的选择性成瘾。
J Virol. 2022 Dec 14;96(23):e0136022. doi: 10.1128/jvi.01360-22. Epub 2022 Nov 23.
4
Targeting of BCL2 Family Proteins with ABT-199 and Homoharringtonine Reveals BCL2- and MCL1-Dependent Subgroups of Diffuse Large B-Cell Lymphoma.使用ABT-199和高三尖杉酯碱靶向BCL2家族蛋白揭示弥漫性大B细胞淋巴瘤中依赖BCL2和MCL1的亚组
Clin Cancer Res. 2016 Mar 1;22(5):1138-49. doi: 10.1158/1078-0432.CCR-15-1191. Epub 2015 Oct 14.
5
MCL1 gene silencing promotes senescence and apoptosis of glioma cells via inhibition of the PI3K/Akt signaling pathway.MCL1 基因沉默通过抑制 PI3K/Akt 信号通路促进胶质瘤细胞衰老和凋亡。
IUBMB Life. 2019 Jan;71(1):81-92. doi: 10.1002/iub.1944. Epub 2018 Oct 8.
6
The selectivity of Marinopyrrole A to induce apoptosis in MCL1 BCL2 expressing myeloma cells is related to its ability to impair protein translation.海吡咯菌素A诱导表达MCL1 BCL2的骨髓瘤细胞凋亡的选择性与其损害蛋白质翻译的能力有关。
Br J Haematol. 2018 Jan;180(1):157-159. doi: 10.1111/bjh.14293. Epub 2016 Aug 14.
7
Correlation Between BCL2 and Mcl1 Single Nucleotide Polymorphisms and Chemotherapy Response in Jordanian Patients with Colorectal Cancer.BCL2 和 Mcl1 单核苷酸多态性与约旦结直肠癌患者化疗反应的相关性。
Curr Pharm Biotechnol. 2021;22(5):646-653. doi: 10.2174/1389201021666200703200126.
8
Understanding MCL1: from cellular function and regulation to pharmacological inhibition.理解 MCL1：从细胞功能和调控到药理学抑制。
FEBS J. 2022 Oct;289(20):6209-6234. doi: 10.1111/febs.16136. Epub 2021 Aug 2.
9
NOXA-mediated degradation of MCL1 and BCL2L1 causes apoptosis of daunorubicin-treated human acute myeloid leukemia cells.NOXA 介导的 MCL1 和 BCL2L1 降解导致柔红霉素处理的人急性髓系白血病细胞凋亡。
J Cell Physiol. 2021 Nov;236(11):7356-7375. doi: 10.1002/jcp.30407. Epub 2021 May 13.
10
Cytoplasmic Blebs in T-Cell Prolymphocytic Leukemia.
N Engl J Med. 2019 Jun 13;380(24):2360. doi: 10.1056/NEJMicm1814629.
引用本文的文献
1
Prolymphocytic Leukaemia: an Update on Biology and Treatment.慢性淋巴细胞白血病：生物学和治疗的最新进展。
Curr Oncol Rep. 2024 Feb;26(2):129-135. doi: 10.1007/s11912-023-01485-3. Epub 2024 Jan 2.
2
The mitochondrial anti-apoptotic dependencies of hematologic malignancies: from disease biology to advances in precision medicine.血液系统恶性肿瘤中线粒体抗凋亡的依赖性：从疾病生物学到精准医学的进展。
Haematologica. 2022 Apr 1;107(4):790-802. doi: 10.3324/haematol.2021.280201.
3
Hijacking the Pathway: Perspectives in the Treatment of Mature T-cell Leukemias.劫持通路：成熟T细胞白血病的治疗前景
Hemasphere. 2021 Jun 1;5(6):e573. doi: 10.1097/HS9.0000000000000573. eCollection 2021 Jun.
4
Venetoclax treatment of patients with relapsed T-cell prolymphocytic leukemia.维奈托克治疗复发的T细胞幼淋巴细胞白血病患者。
Blood Cancer J. 2021 Mar 2;11(3):47. doi: 10.1038/s41408-021-00443-1.
5
Rationale for the combination of venetoclax and ibrutinib in T-prolymphocytic leukemia.维奈托克与伊布替尼联合用于T-原淋巴细胞白血病的原理。
Haematologica. 2021 Aug 1;106(8):2251-2256. doi: 10.3324/haematol.2020.271304.
6
MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents.MCL-1 抑制剂：新型抗癌药物的快速发展通道。
J Hematol Oncol. 2020 Dec 11;13(1):173. doi: 10.1186/s13045-020-01007-9.
7
Inhibition of the anti-apoptotic protein MCL-1 severely suppresses human hematopoiesis.抑制抗凋亡蛋白 MCL-1 会严重抑制人类造血。
Haematologica. 2021 Dec 1;106(12):3136-3148. doi: 10.3324/haematol.2020.252130.
本文引用的文献
1
Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy.维奈托克单药治疗在接受布鲁顿酪氨酸激酶抑制剂治疗后复发、难治性套细胞淋巴瘤患者中的疗效。
Haematologica. 2019 Feb;104(2):e68-e71. doi: 10.3324/haematol.2018.198812. Epub 2018 Sep 6.
2
Responses to the Selective Bruton's Tyrosine Kinase (BTK) Inhibitor Tirabrutinib (ONO/GS-4059) in Diffuse Large B-cell Lymphoma Cell Lines.弥漫性大B细胞淋巴瘤细胞系对选择性布鲁顿酪氨酸激酶（BTK）抑制剂替拉鲁替尼（ONO/GS-4059）的反应。
Cancers (Basel). 2018 Apr 23;10(4):127. doi: 10.3390/cancers10040127.
3
First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia.首例 T 细胞前淋巴细胞白血病中 BCL-2 抑制剂 venetoclax 的人体反应。
Blood. 2017 Dec 7;130(23):2499-2503. doi: 10.1182/blood-2017-05-785683. Epub 2017 Sep 27.
4
Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling.高通量体外药物测试和突变分析发现 T-PLL 的新型药物敏感性。
Leukemia. 2018 Mar;32(3):774-787. doi: 10.1038/leu.2017.252. Epub 2017 Aug 14.
5
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma.维奈托克在复发或难治性非霍奇金淋巴瘤患者中的I期首次人体研究。
J Clin Oncol. 2017 Mar 10;35(8):826-833. doi: 10.1200/JCO.2016.70.4320. Epub 2017 Jan 17.
6
The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models.MCL1 抑制剂 S63845 在多种癌症模型中具有良好的耐受性和疗效。
Nature. 2016 Oct 27;538(7626):477-482. doi: 10.1038/nature19830. Epub 2016 Oct 19.
7
Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Venetoclax 治疗伴有 17p 缺失的复发或难治性慢性淋巴细胞白血病：一项多中心、开放标签、2 期研究。
Lancet Oncol. 2016 Jun;17(6):768-778. doi: 10.1016/S1470-2045(16)30019-5. Epub 2016 May 10.
8
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.在复发的慢性淋巴细胞白血病中使用维奈托克靶向BCL2
N Engl J Med. 2016 Jan 28;374(4):311-22. doi: 10.1056/NEJMoa1513257. Epub 2015 Dec 6.
9
Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy.利用选择性 BCL-2 家族抑制剂来剖析细胞存活的依赖性，并定义改善癌症治疗的策略。
Sci Transl Med. 2015 Mar 18;7(279):279ra40. doi: 10.1126/scitranslmed.aaa4642.
10
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.ABT-199，一种强效和选择性的 BCL-2 抑制剂，在发挥抗肿瘤活性的同时不影响血小板。
Nat Med. 2013 Feb;19(2):202-8. doi: 10.1038/nm.3048. Epub 2013 Jan 6.
Zotero 插件